Betsy Rader Launches TV ad focused on prescription drug prices

Tuesday, September 18, 2018
Contact: Brexton Isaacs,

Betsy Rader Launches TV ad focused on prescription drug prices
Rader commits to taking on drug companies and working to lower pharmaceutical costs

Novelty, OH – On Tuesday, Betsy Rader’s campaign for Congress started airing her second TV ad of the cycle. In the ad, Betsy is sitting around a table with a group of voters, talking about her commitment to taking on the pharmaceutical industry and fighting to bring down the cost prescription drugs.

In the ad, Rader notes that she has worked at the Centers for Medicare and Medicaid Services and knows that the drug companies will continue to raise prices unless Congress takes action. She calls out Congressman David Joyce for taking contributions from the pharmaceutical industry while voting to give them a big tax cut.

“Almost every day, I’m in a living room, at a town hall, or around a kitchen table having conversations with voters about the issues they care most about in this election. Time and again, I hear from folks that the top issues on their minds are the rising costs of healthcare and prescription drugs. It breaks my heart hearing from people  who are going without their medications because the costs keep going up–we have to take action immediately,” said Betsy Rader. “Instead of working to lower the cost of prescription drugs, Congressman Joyce voted to give a huge tax cut to the pharmaceutical industry, which has donated over $100 thousand to his campaigns. I’ve refused to take their money and, when I’m in Congress, I will fight to bring down the costs of prescription drugs.”

Click here to watch the ad.

Rader has proposed, among other solutions, changing the law to allow Medicare to negotiate prices of prescription drugs and prohibiting “pay-for-delay” deals that slow generic drugs from entering the market. These actions would create immediate benefits for patients while costing taxpayers nothing, and even saving taxpayer money through reduced costs.

Rader’s new ad comes on the heels of her first ad, in which she is riding her bike and sharing the story of being hit by a car while riding her bike as a kid–noting that she’s had back problems ever since and eventually had to get a spinal fusion. She highlights her commitment to fighting for protections for people with pre-existing conditions and to make healthcare affordable for everyone.

Rep. David Joyce has yet to air an ad on broadcast TV. Last month, Joyce aired a misleading ad on cable that’s been criticized by pieces in Akron Beacon Journal, Plain Dealer/, The Washington Post, The New York Times, and SLATE for attempting to distance himself from his long record advocating for repeal and voting 31 times to repeal the Affordable Care Act and, with it, protections for people with pre-existing conditions.

Axios: Pharma’s $50 billion tax windfall for investors
The pharmaceutical industry is using a large portion of its windfall from Republicans’ corporate tax cuts to boost its stock prices. Nine drug companies are spending a combined $50 billion on new share buyback programs, a sum that towers over investments in employees or drug research and development. The bottom line: All of those buybacks were announced during or after the passage of the Republican tax bill. That money is enriching hedge funds, other Wall Street investors and top drug company executives, but it isn’t necessarily helping patients.

News-Herald: Democrat running for Dave Joyce’s seat says she won’t take corporate PAC money
A Democratic candidate challenging for the Ohio’s 14th District U.S. Congressional seat has announced she will not take money from corporate political action committees…Rader is taking the pledge not to accept corporate PAC funds because of the “corrosive impact that corporate special interests have in our democracy.”

Kaiser Family Foundation: Searching for Savings in Medicare Drug Price Negotiations
In response to higher drug spending growth and heightened attention to drug prices, some policymakers and experts have proposed allowing Medicare to negotiate the price of prescription drugs. Under current law, the Secretary of the Department of Health and Human Services (HHS) is explicitly prohibited from negotiating directly with drug manufacturers on behalf of Medicare Part D enrollees.

AARP: Pay-for-Delay Agreements and Prescription Drug Costs
Brand-name pharmaceutical companies can delay generic competition by paying a generic competitor to hold its competing product off the market for a certain period of time. These “pay-for-delay” agreements benefit both parties: the brand-name manufacturer can continue to charge monopoly prices, and the generic company is compensated for its inaction.